Envista (NVST) Q1 2026 earnings review
Robust Top-Line Growth Defies Macro Jitters, But Cash Flow Reverses
Envista delivered a powerful Q1, beating expectations with 9.5% core revenue growth and a 50% YoY surge in adjusted EPS to $0.36. Growth was broad-based, fueled by both the Specialty Products & Technologies (+8.4% core) and Equipment & Consumables (+11.5% core) segments. Margin expansion was equally impressive, with adjusted EBITDA margins climbing 120 bps year-over-year. However, the income statement's strength is completely contradicted by the cash flow statement. Operating cash flow and free cash flow both flipped negative due to a sudden buildup in working capital. Furthermore, management's decision to maintain a conservative 2-4% full-year growth guidance mathematically implies a severe deceleration for the remainder of the year.
🐂 Bull Case
Adjusted EBITDA grew 25% YoY, far outpacing the 9.5% sales growth. This 120 bps margin expansion proves that operational restructuring and the EBS methodology are yielding powerful operating leverage.
The E&C segment accelerated to 11.5% core sales growth and expanded adjusted operating margins to 21.0% from 18.1%, shaking off historic macro pressures.
🐻 Bear Case
Net income grew, but Operating Cash Flow dropped to a negative -$3.3M. This was driven by a $40M reduction in accrued liabilities and a sudden spike in inventory and receivables.
By maintaining the 2-4% full-year core growth guide despite a 9.5% Q1, management implicitly forecasts a sharp deceleration to low-single-digit or flat growth for the next three quarters.
⚖️ Verdict: ⚪
Neutral. The income statement is incredibly bullish, showcasing excellent execution. But a 9.5% growth quarter paired with negative free cash flow and a refusal to raise annual guidance is a major red flag that demands caution.
Key Themes
Equipment & Consumables Leads Acceleration
The E&C segment was the standout performer, accelerating to 11.5% core sales growth (up from 10.7% in 25Q4 and 1.7% a year ago). Adjusted operating margin also improved dramatically to 21.0% from 18.1% in 25Q1, proving that new product commercialization and increased customer engagement are driving highly profitable volume.
Cash Flow Reversing Amid Working Capital Buildup
A significant concern emerged on the balance sheet: Operating Cash Flow reversed from $0.3M in 25Q1 to a negative -$3.3M in 26Q1, moving in the exact opposite direction of Net Income (which doubled to $38.7M). This was caused by heavy working capital consumption: a $39.8M decrease in accrued expenses, alongside an increase in both inventories ($9.6M) and receivables ($13.3M). If revenue is growing, receivables and inventory logically expand, but burning cash to support it is unsustainable long-term.
EBS-Driven Margin Expansion
The Envista Business System (EBS) continues to be the primary engine for profitability. Broad-based operational improvements supported 100 bps of gross margin expansion (to 55.8% adjusted) and 120 bps of adjusted EBITDA margin expansion (to 14.0%). Management achieved this without starving the business, simultaneously funding double-digit increases in R&D and Sales & Marketing investments.
Aggressive Capital Returns Signal Confidence
In a clear signal of confidence regarding future cash generation, the Board authorized a new $300 million share repurchase program. This comes immediately after the company repurchased 1.6 million shares for $43 million in Q1, utilizing almost all of the previous authorization. Shrinking the share count provides a solid structural floor for future EPS growth.
Macro Uncertainty Caps Outlook
Despite a massive Q1 beat, CEO Paul Keel explicitly framed the results 'in the context of macro uncertainty.' This aligns with prior quarters' commentary regarding sluggish underlying dental markets and global consumer pressures. The fact that the company did not raise guidance suggests management views the Q1 strength as a temporary reprieve rather than a structural end to the challenging macro environment.
Implied Deceleration Contradicts Positive Narrative
Management's decision to maintain the 2% to 4% full-year core growth guidance mathematically forces a pessimistic view for the rest of 2026. To hit a 3% midpoint for the year after growing 9.5% in Q1, the company must average less than 1% core growth over the next three quarters. The narrative of 'momentum continuing' contradicts the brutal deceleration baked into their own outlook.
Other KPIs
Stable. While slightly trailing the E&C segment, SPT delivered a solid 8.4% core revenue increase. Adjusted operating margins remained relatively flat YoY at 14.5% (vs 14.1% in 25Q1), indicating that growth in this higher-tech segment—which includes Nobel Biocare and Ormco—is steady but lacks the outsized operating leverage currently driving the E&C segment.
Accelerating. R&D expenses increased 18.5% YoY (from $25.3M in 25Q1). Instead of relying strictly on cost-cutting to hit margin targets, Envista is aggressively funding innovation to protect market share.
Guidance
Decelerating. Reaffirming this guidance range after achieving 9.5% core growth in Q1 implies that management expects top-line growth to collapse to roughly 0-2% for the remaining three quarters, likely due to much tougher YoY comparables in the second half of the year.
Decelerating. Q1 achieved an explosive 25% YoY growth in adjusted EBITDA. The 7-13% annual guidance implies that margin expansion will moderate significantly throughout the remainder of 2026.
Decelerating. The midpoint of $1.40 represents roughly 17.6% growth over FY25's $1.19. Because Q1 adjusted EPS grew 50% YoY, the guidance bakes in a noticeably slower trajectory through the rest of the year.
Reversing. Q1 free cash flow was deeply negative (-$15.7M). To hit 100% conversion of adjusted net income for the full year, Envista must engineer a massive, immediate reversal in its working capital consumption over the next nine months.
Key Questions
The Guidance Disconnect
With Q1 core sales growth printing at 9.5%, what specific macroeconomic or market-level headwinds are driving the decision to maintain the conservative 2-4% full-year guidance?
Working Capital Reversal
Operating cash flow turned negative this quarter due to a sharp $40M decline in accrued expenses and steady increases in inventory. What is the specific timeline for normalizing this working capital drag to hit your 100% free cash conversion target?
E&C Segment Growth Sustainability
How much of the impressive 11.5% core growth in Equipment & Consumables was driven by new product launches versus underlying baseline market recovery or distributor restocking?
Share Repurchase Timing
With a newly authorized $300M share repurchase program and cash flows currently constrained by working capital, how aggressively do you plan to deploy this capital over the remainder of FY26?